$2.5 Billion is the total value of HealthCor Management, L.P.'s 72 reported holdings in Q2 2021. The portfolio turnover from Q1 2021 to Q2 2021 was - .
| Value | Shares | ↓ Weighting | ||||||
|---|---|---|---|---|---|---|---|---|
| REGN | New | REGENERON PHARMACEUTICALS | $106,335,000 | – | 190,380 | +100.0% | 4.25% | – |
| CVS | New | CVS HEALTH CORP | $105,746,000 | – | 1,267,330 | +100.0% | 4.23% | – |
| BMY | New | BRISTOL-MYERS SQUIBB CO | $98,517,000 | – | 1,474,370 | +100.0% | 3.94% | – |
| TMO | New | THERMO FISHER SCIENTIFIC INC | $92,303,000 | – | 182,970 | +100.0% | 3.69% | – |
| NTRA | New | NATERA INC | $89,650,000 | – | 789,658 | +100.0% | 3.58% | – |
| SYK | New | STRYKER CORPORATION | $70,956,000 | – | 273,190 | +100.0% | 2.84% | – |
| NVRO | New | NEVRO CORP | $62,392,000 | – | 376,330 | +100.0% | 2.49% | – |
| UHS | New | UNIVERSAL HLTH SVCS INCcl b | $47,674,000 | – | 325,577 | +100.0% | 1.91% | – |
| AMGN | New | AMGEN INC | $38,581,000 | – | 158,280 | +100.0% | 1.54% | – |
| NBIX | New | NEUROCRINE BIOSCIENCES INC | $37,953,000 | – | 389,980 | +100.0% | 1.52% | – |
| THC | New | TENET HEALTHCARE CORP | $25,200,000 | – | 376,180 | +100.0% | 1.01% | – |
| INCY | New | INCYTE CORPcall | $22,463,000 | – | 267,000 | +100.0% | 0.90% | – |
| LGV | New | LONGVIEW ACQUISITION CORP II | $20,932,000 | – | 2,135,900 | +100.0% | 0.84% | – |
| DCPH | New | DECIPHERA PHARMACEUTICALS IN | $14,138,000 | – | 386,190 | +100.0% | 0.56% | – |
| LIVN | New | LIVANOVA PLC | $10,514,000 | – | 125,000 | +100.0% | 0.42% | – |
| MSAC | New | MEDICUS SCIENCES ACQUISITION | $7,180,000 | – | 744,000 | +100.0% | 0.29% | – |
| RAPT | New | RAPT THERAPEUTICS INC | $6,358,000 | – | 200,000 | +100.0% | 0.25% | – |
| GHRS | New | GH RESEARCH PLCordinary shares | $5,433,000 | – | 250,000 | +100.0% | 0.22% | – |
| OHPA | New | ORION ACQUISITION CORP | $5,290,000 | – | 547,598 | +100.0% | 0.21% | – |
| CMLT | New | CM LIFE SCIENCES III INC | $5,160,000 | – | 500,000 | +100.0% | 0.21% | – |
| NVAX | New | NOVAVAX INCput | $4,989,000 | – | 23,500 | +100.0% | 0.20% | – |
| CYT | New | CYTEIR THERAPEUTICS INC | $2,568,000 | – | 120,000 | +100.0% | 0.10% | – |
| DAWN | New | DAY ONE BIOPHARMACEUTICALS I | $2,362,000 | – | 103,717 | +100.0% | 0.09% | – |
| GLUE | New | MONTE ROSA THERAPEUTICS INC | $2,270,000 | – | 100,000 | +100.0% | 0.09% | – |
| ATAI | New | ATAI LIFE SCIENCES NV | $1,388,000 | – | 75,000 | +100.0% | 0.06% | – |
| ELEV | New | ELEVATION ONCOLOGY INC | $1,357,000 | – | 100,000 | +100.0% | 0.05% | – |
| BHVN | New | BIOHAVEN PHARMACTL HLDG CO L | $1,068,000 | – | 11,000 | +100.0% | 0.04% | – |
| LGVWS | New | LONGVIEW ACQUISITION CORP II*w exp 99/99/999 | $585,000 | – | 427,178 | +100.0% | 0.02% | – |
| CMLTW | New | CM LIFE SCIENCES III INC*w exp 04/30/202 | $258,000 | – | 99,998 | +100.0% | 0.01% | – |
| OHPAW | New | ORION ACQUISITION CORP*w exp 02/19/202 | $131,000 | – | 137,305 | +100.0% | 0.01% | – |
| MSACW | New | MEDICUS SCIENCES ACQUISITION*w exp 02/12/202 | $83,000 | – | 82,663 | +100.0% | 0.00% | – |
Original filings
The following EDGAR filing(s) were analyzed to create this report:
- View 13F-HR filed 2021-08-16
Signatures
The EDGAR filing(s) were signed by:
Top long-term holdings
| Name | Quarters owned | Latest quarter owned | Max weighting |
|---|---|---|---|
| HCA HOLDINGS INC | 27 | Q1 2022 | 6.2% |
| ZIMMER HLDGS INC | 26 | Q2 2022 | 9.3% |
| DANAHER CORPORATION | 26 | Q3 2022 | 5.6% |
| NEUROCRINE BIOSCIENCES INC | 26 | Q4 2022 | 7.8% |
| UNITEDHEALTH GROUP INC | 24 | Q3 2022 | 6.4% |
| VERTEX PHARMACEUTICALS INC | 24 | Q3 2021 | 5.3% |
| HUMANA INC | 22 | Q3 2022 | 6.6% |
| BRISTOL-MYERS SQUIBB CO | 22 | Q3 2022 | 9.2% |
| BIOGEN INC | 21 | Q3 2022 | 8.5% |
| LABORATORY CORP AMER HLDGS | 20 | Q2 2020 | 8.3% |
View HealthCor Management, L.P.'s complete holdings history.
Latest significant ownerships (13-D/G)
| Filed | Shares | Percentage | |
|---|---|---|---|
| CareView Communications Inc | May 26, 2023 | 186,970,000 | 32.0% |
| Research Alliance Corp. IISold out | February 14, 2023 | 0 | 0.0% |
| ARYA Sciences Acquisition Corp IVSold out | February 14, 2022 | 0 | 0.0% |
| Aurinia Pharmaceuticals Inc.Sold out | February 14, 2022 | 0 | 0.0% |
| MADRIGAL PHARMACEUTICALS, INC.Sold out | February 14, 2022 | 0 | 0.0% |
| Medicus Sciences Acquisition Corp.Sold out | February 14, 2022 | 0 | 0.0% |
| Arcturus Therapeutics Holdings Inc.Sold out | February 12, 2021 | 0 | 0.0% |
| Intersect ENT, Inc.Sold out | February 12, 2021 | 0 | 0.0% |
| NEVRO CORP | February 12, 2021 | 156,046 | 0.5% |
| ViewRay, Inc.Sold out | February 12, 2021 | 0 | 0.0% |
View HealthCor Management, L.P.'s complete significant-ownership history.
Latest filings
| Type | Filed |
|---|---|
| 4 | 2023-05-26 |
| 4 | 2023-05-26 |
| SC 13D/A | 2023-05-26 |
| 4 | 2023-04-04 |
| 4 | 2023-04-04 |
| SC 13D/A | 2023-04-03 |
| 13F-HR | 2023-02-15 |
| SC 13G/A | 2023-02-14 |
| 4 | 2023-01-04 |
| 4 | 2023-01-04 |
View HealthCor Management, L.P.'s complete filings history.
All filings
- Holdings (13F-HR)
- Significant ownership (13-D/G)
- Insider transactions (4, 5, 6)
- Events (8-K)
- Shareholder votes (proxy)
View complete filings history.